Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a significant drop in short interest in October. As of October 31st, there was short interest totalling 23,500 shares, a drop of 20.6% from the October 15th total of 29,600 shares. Approximately 1.4% of the company’s stock are sold short. Based on an average daily volume of 31,700 shares, the short-interest ratio is currently 0.7 days.

Creative Medical Technology Stock Up 1.5 %

Shares of CELZ stock traded up $0.04 during trading hours on Friday, hitting $2.70. 20,410 shares of the company’s stock traded hands, compared to its average volume of 71,907. The stock’s fifty day simple moving average is $3.46 and its two-hundred day simple moving average is $3.69. Creative Medical Technology has a 12-month low of $2.52 and a 12-month high of $10.28. The stock has a market cap of $4.73 million, a price-to-earnings ratio of -0.71 and a beta of 2.01.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Virtu Financial LLC bought a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,374 shares of the company’s stock, valued at approximately $85,000. Virtu Financial LLC owned 1.21% of Creative Medical Technology as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.